{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T02:55:40Z","timestamp":1774580140893,"version":"3.50.1"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s00393-024-01474-2","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T15:02:15Z","timestamp":1705676535000},"page":"151-152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Sarilumab bei Polymyalgia rheumatica","Sarilumab for polymyalgia rheumatica"],"prefix":"10.1007","volume":"83","author":[{"given":"Wolfgang A.","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,19]]},"reference":[{"issue":"6","key":"1474_CR1","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1136\/annrheumdis-2021-221126","volume":"81","author":"M Bonelli","year":"2022","unstructured":"Bonelli\u00a0M, Radner\u00a0H, Kerschbaumer et\u00a0al (2022) Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a\u00a0phase\u00a02\/3 randomised controlled trial. Ann Rheum Dis 81(6):838\u2013844","journal-title":"Ann Rheum Dis"},{"key":"1474_CR2","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00393-018-0476-8","volume":"77","author":"F Buttgereit","year":"2018","unstructured":"Buttgereit\u00a0F, Brabant\u00a0T, Dinges\u00a0H et\u00a0al (2018) S3-Leitlinie zur Behandlung der Polymyalgia rheumatica. Z\u00a0Rheumatol 77:429\u2013441","journal-title":"Z Rheumatol"},{"issue":"11","key":"1474_CR3","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/jama.2022.15459","volume":"328","author":"V Devauchelle-Pensec","year":"2022","unstructured":"Devauchelle-Pensec\u00a0V, Carvajal-Alegria\u00a0G, Dernis\u00a0E et\u00a0al (2022) Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a\u00a0randomized clinical trial. JAMA 328(11):1053\u20131062","journal-title":"JAMA"},{"key":"1474_CR4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13075-023-03177-6","volume":"25","author":"WA Schmidt","year":"2023","unstructured":"Schmidt\u00a0WA, Dasgupta\u00a0B, Lazar\u00a0SJ et\u00a0al (2023) A phase\u00a03 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis. Arthritis Res Ther 25:199","journal-title":"Arthritis Res Ther"},{"key":"1474_CR5","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1056\/NEJMoa2303452","volume":"389","author":"RF Spiera","year":"2023","unstructured":"Spiera\u00a0RF, Unizony\u00a0S, Warrington\u00a0KJ et\u00a0al (2023) Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper. N\u00a0Engl J Med 389:1263\u20131272","journal-title":"N Engl J Med"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01474-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-024-01474-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01474-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T15:06:52Z","timestamp":1709132812000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-024-01474-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1474"],"URL":"https:\/\/doi.org\/10.1007\/s00393-024-01474-2","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,19]]},"assertion":[{"value":"17 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.A.\u00a0Schmidt: Referent f\u00fcr AbbVie, Chugai, GlaxoSmithKline, Medac, Novartis, Roche, Sanofi. Berater f\u00fcr AbbVie, Fresenius Kabi, GlaxoSmithKline, Novartis, Sanofi. Studienleiter von Studien von AbbVie, GlaxoSmithKline, Novartis und Sanofi.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}